Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025

Reuters

10/06

Context <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025

Context Therapeutics Inc. has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a "Trial in Progress" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager (TCE) for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540351-en) on October 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573671135"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573671135\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573671135?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573671135","market":"us","top_or_hot":-1,"title":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Context <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTX\">Context Therapeutics Inc.</a> has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a \"Trial in Progress\" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager (TCE) for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540351-en) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContext Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-06 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Context <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTX\">Context Therapeutics Inc.</a> has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a \"Trial in Progress\" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager (TCE) for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540351-en) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL18BYyK:1","article_id":"2573671135","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573671135","pubTimestamp":1759750258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025. Context Therapeutics Inc. has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's  40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a \"Trial in Progress\" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager  for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","CNTX":"Context Therapeutics Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股"},"translate_title":"Context Therapeutics在SITC 2025上宣布CT-95双特异性T细胞衔接剂治疗晚期实体瘤的1期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTX":0.9,"NDAQ":0.9},"content_text":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025\n    \n\nContext Therapeutics Inc. has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a \"Trial in Progress\" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager (TCE) for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540351-en) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}